Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Gaut D, Oliai C, Boiarsky J, Zhang S, et al. Leuk Lymphoma 2023 Oct 6:1-9. doi: 10.1080/10428194.2023.2264426.

Read + Share

Amedeo Smart

Independent Medical Education

Gaut D, Oliai C, Boiarsky J, Zhang S, et al. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma 2023 Oct 6:1-9. doi: 10.1080/10428194.2023.2264426.
PMID: 37801340